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Abstract 
Changes in the 4th edition of the WHO Classification of Head and Neck Tumours are 
reviewed focusing on their impact on the surgical care of diseases affecting the salivary 
glands, jaws and oral cavity.  Updates to the salivary chapter include the addition of 
secretory carcinoma and sclerosing polycystic adenosis.  The odontogenic cysts are back 
and the odontogenic keratocyst is listed among them, having lost its brief and confusing 
designation as a neoplasm.   The newly defined sclerosing odontogenic carcinoma and 
primordial odontogenic tumour are added.  Oropharyngeal tumours have been separated 
from the oral cavity tumours, reflecting the great importance of HPV in carcinoma of the 
tonsils.  The problems of grading oral epithelial dysplasia persist.   
Keywords: Pathology, Tumour, Oral, Salivary, Jaws, WHO, Classification 
 
Introduction 
The WHO text (1) is a classification of tumours with an emphasis on neoplasms and aims to 
achieve consistent nomenclature and diagnosis of tumours across the globe.  This should 
facilitate epidemiological research with accurate comparisons of incidence between 
countries as well as effective transfer of treatments and diagnostic tests. In its 4th edition, 
the WHO Classification of Head and Neck Tumours contains new additions, updates and 
reclassifications.  The changes reflect an improved understanding of the morphological and 
behavioural range of head and neck tumours.  There is much greater detail on the molecular 
drivers of neoplasia and it is hoped this will facilitate greater use of targeted therapies in the 
future.  
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Odontogenic and maxillofacial bone tumours 
This chapter is expanded to include the odontogenic cysts [omitted in the previous edition 
(2)] as well as benign and malignant tumours of bone and cartilage.   There have been 
changes in the nomenclature for odontogenic tumours, some providing a helpful 
simplification but others having the potential to cause confusion.    
 
Malignant odontogenic tumours 
The classification of malignant odontogenic tumours has been simplified.  There is now only 
one ameloblastic carcinoma, one primary intraosseous carcinoma and one odontogenic 
sarcoma.  Odontogenic carcinosarcoma, eliminated in the previous edition, has been 
included with a small number of well-defined cases referenced.  Metastasising 
ameloblastoma has been moved from the malignant section to the benign bringing it into line 
with the benign metastasizing pleomorphic adenoma.    Metastasising ameloblastoma does 
show a benign microscopic appearance at both the primary and metastatic sites.  The most 
common sites of metastasis are the lungs followed by cervical lymph nodes.  The overall 
mean 5-year survival is just 44%.  Cases with cervical lymph node metastases only and 
managed by surgery do appear to have a better survival, although data are very limited (3).   
 
The only newly defined malignant odontogenic tumour included is the rare and recently 
described sclerosing odontogenic carcinoma (4-9).   Reported cases have been in men and 
women between 40-70 years of age.  Presentation is as an expansile masses sometimes 
with nerve signs.  There is a relatively even distribution between the maxilla and mandible 
with variable cortical destruction and tooth resorption (4-8).  The cytological features are 
bland but an aggressive pattern of infiltration into muscle and nerve is seen.  The carcinoma 
extends beyond what appear at surgery to be clear margins (3) and the tumour recurs after 
curettage alone (5).  Resection with a 5mm margin has been recommended (8).   Neck 
dissection, chemotherapy and radiotherapy have also been used (4-5).  However, no 
metastases nor disease related deaths have been reported and the need for adjunctive 
therapies is not clear. It is important to recognise this entity, so that its aggressive 
histological appearance does not lead to overtreatment.    
 
Benign odontogenic tumours 
Ameloblastic fibro-dentinoma and ameloblastic fibro-odontoma are now considered by most 
authorities to be developing odontomas and have been removed.  The 
odontoameloblastoma was previously described as a distinct entity combining the features of 
an ameloblastoma with those of an odontoma.  It still has a brief mention in the section on 
ameloblastomas as it is now considered to be an ameloblastoma that has grown around, or 
originated in, the follicle of an odontoma or developing tooth.  Ossifying fibroma is given a 
section amongst the benign odontogenic tumours under the term cemento-ossifying fibroma.  
This better reflects its odontogenic origin but has no implications for its management.  
 
The classification of ameloblastomas remains contentious especially regarding unicystic 
types.  The term ameloblastoma, solid/multicystic type has been replaced by ameloblastoma 
without further qualification which may cause some confusion.  Many pathologists are likely 
to continue using the term solid/multicystic to differentiate the conventional ameloblastoma 
from unicystic and other variants.  Ameloblastoma, unicystic type retains its full and 
descriptive name.  The unicystic ameloblastoma without invasion of its wall can probably be 
managed more conservatively than the solid/multicystic type (10-11) but there is a lack of 
follow up studies and unicystic ameloblastomas do appear to recur, albeit less frequently 
than solid/multicystic types.  Clear differentiation between types of ameloblastoma would 
therefore seem essential, although diagnosis of a unicystic ameloblastoma without mural 
invasion can only be confirmed on examination of the entire excision specimen.  It remains 
to be seen to what extent this new classification will be accepted and it would seem likely 
that the growing understanding of the mutational drivers of ameloblastomas will assist in 
predicting behaviour and allow for more targeted therapies (12).  A significant proportion of 
ameloblastomas carry a mutation of BRAF (13), as in some melanomas and thyroid 
carcinomas.  There is emerging evidence that ameloblastomas carrying this BRAF mutation 
follow a more aggressive course (14). 
 
The only newly defined benign odontogenic tumour added is the primordial odontogenic 
tumour described in a series of six patients (15) all in the first two decades of life with an 
even gender distribution.   All presented with an asymptomatic swelling in the posterior 
mandible (5 cases) or the posterior maxilla (1 case).   Imaging showed well-defined 
radiolucencies (35-90 mm in maximum dimension) associated with unerupted variably 
resorbed or displaced teeth in an apparent pericoronal relationship.  The tumours were solid 
and well circumscribed comprising loose fibrous tissue with tissue similar to the dental 
papilla and a characteristic complete peripheral lining of cuboidal to columnar epithelium.  
The lesions were easily enucleated and no recurrences reported with up to 20 years of 
follow up. 
 
Odontogenic cysts 
The odontogenic cysts were a notable omission from the previous edition.  This caused 
difficulties both because there is overlap between the histological appearances of cysts and 
odontogenic and salivary neoplasms and because of changes in terminology made at the 
same time.  In the previous edition, the odontogenic keratocyst (OKC) and calcifying 
odontogenic cyst (COC) were listed as keratocystic odontogenic tumour and calcifying cystic 
odontogenic tumour, respectively.  This led to much confusion and the nomenclature was 
not widely accepted.  The propensity for recurrence together with association with PTCH 
gene mutations (16) had been taken as supportive of a neoplastic designation for the OKC.  
However, not all OKCs possess identifiable PTCH mutations (17) and it was not clear 
whether the neoplastic designation was meant to apply to all OKCs or just a subset, as cysts 
were omitted.  The 2017 WHO panel did not believe there was sufficient evidence to justify 
classification as a neoplasm and the designations OKC and COC are back as the preferred 
terms, though the 2005 terms remain acceptable synonyms.  
Maxillofacial bone tumours 
 Benign and malignant tumours of bone and cartilage are now described in the same chapter 
as the odontogenic tumours allowing for features specific to the gnathic bones to be 
emphasised.  In terms of patient care, this is most relevant for osteosarcoma, which has a 
lower propensity for metastasis when arsing in the gnathic bones compared to the other 
skeletal sites.  Indeed, resection with clear margins is the most important prognostic factor 
for osteosarcoma of the jaws, with the role of (neo)adjuvant therapy remaining controversial 
(18).   
 
Key points 
• Sclerosing odontogenic carcinoma is a recently described entity that despite its 
aggressive microscopic appearance carries a good prognosis.  No metastatic spread nor 
disease related deaths have been reported. 
• Metastasising ameloblastoma is now defined as benign, despite carrying a significant 
mortality rate. 
• Ameloblastic fibro-dentinoma and ameloblastic fibro-odontoma are considered to be 
stages in developing odontomas and may be treated by enucleation. 
• Primordial odontogenic tumour is an emerging entity seen in young people and 
appears to be adequately managed by enucleation. 
• Odontogenic keratocyst is reinstated as the preferred term for keratocystic 
odontogenic tumour, reflecting its probable non-neoplastic nature. 
 
Tumours of the Salivary Glands 
A multitude of different epithelial tumours arise in the salivary glands with many subtypes 
suggested.   Only well documented epithelial neoplasms are included often with supporting 
genetic data.  The soft tissue section of the chapter has been expanded and a section on 
non-neoplastic epithelial lesions added.      
 
Benign salivary tumours 
There have been no recently recognised entities added to this section.  Metastasising 
pleomorphic adenoma was previously listed as a distinct entity in the malignant tumours 
section.  It now occupies a subcategory of pleomorphic adenoma within the benign tumours 
section.  Metastasising pleomorphic adenoma cannot be distinguished histologically from a 
typical pleomorphic adenoma and is only diagnosed on detection of metastases usually 
following multiple local recurrences.  In a well-documented series of 11 cases, 2 patients 
died as a direct result of metastatic tumour (19).  But recognition of the lesion as a benign 
entity may allow more aggressive metastastecomy as a treatment, particularly when 
metastases are few.  
 
Non-neoplastic epithelial lesions   
The new additions of nodular oncocytic hyperplasia, intercalated duct hyperplasia and 
sclerosing polycystic adenosis are included in this new section.  Nodular oncocytic 
hyperplasia is a benign non-neoplastic nodular proliferation occurring in the parotid gland.  
Intercalated duct hyperplasia is similarly rare and usually an incidental finding in excisions 
made for other salivary tumours. 
 
Sclerosing polycystic adenosis (Figure 1) was described in the 1990s (20) named for its 
resemblance to fibrocystic change and sclerosing adenosis of the breast.  It appears as a 
painless slow growing mass most commonly in the parotid gland and less frequently the 
submandibular gland and even more rarely in the minor glands. (20-21).  Men and women 
are affected over a wide age range (20-21).  The lesion comprises a lobular well 
circumscribed proliferation of ducts and acini.  Cytological atypia can be present (21-22) and 
there is evidence that this may be a neoplastic rather than reactive process (23).  A single 
case of malignant transformation is described following multiple recurrences (24).  Treatment 
is by complete surgical excision with good margins but a recurrence rate of 19% is reported 
(25).   
Malignant tumours 
The only recently defined entity added to this chapter is secretory carcinoma (Figure 2).  
This was previously described in most publications under the term mammary analogue 
secretory carcinoma (MASC) owing to the morphological similarity to secretory carcinoma of 
breast which is caused by the same ETV6-NTRK3 translocation.  The tumour arises in the 
major and minor glands over a wide age range and without significant gender bias (26-27).  
Presentation is usually as a painless mass (26-28) with a well circumscribed but 
unencapsulated periphery.  The carcinoma appears cytologically low grade (26-27) but has a 
20% incidence of metastases (28).  Prognosis is generally good but worse with increasing 
stage, high grade transformation and possibly atypical fusion transcripts (26,29-30).   
Previous to its definition, cases would likely have been diagnosed as acinic cell carcinoma 
(31).  The higher metastatic rate and possibility of targeted therapies taking advantage of the 
known translocation (32), make correct diagnosis essential.  
 
Intraductal carcinoma is included as a section encompassing entities previous described as 
low grade cribriform cystadenocarcinoma or low grade salivary duct carcinoma.  These rare 
carcinomas show what is described as an intraductal growth pattern and are considered to 
be non-invasive/in situ.   Presentation is usually as an asymptomatic swelling most 
frequently in the parotid gland and rarely in the submandibular or minor glands (33-36).  
Ages of patients in the largest series ranged from 32 to 94 years without significant gender 
bias (33-35).  The designation of “intraductal” is based on the well circumscribed architecture 
and the presence of an intact periphery of myoepithelial cells surrounding an intraluminal 
proliferation of ductal cells.  The cytological features are usually low grade.  The view that an 
intact layer of surrounding myoepithelial cells indicates that the proliferation is an intraductal 
one would seem to assume that the myoepithelial cells are not themselves neoplastic.  The 
justification of this assumption is not clear.  Management is by parotidectomy and no 
recurrences nor metastatic disease have been reported in cases with the usual low grade 
features (34-35).   High grade cytology has been associated with multiple recurrences and 
high grade transformation to widely invasive high grade adenosquamous carcinoma with 
metastatic disease has also been described (33, 37). 
 
Polymorphous low grade adenocarcinoma has been renamed polymorphous 
adenocarcinoma (PAC).  The low grade descriptive term has now been dropped as, whilst 
most are low grade, more aggressive forms are included within the spectrum of this 
diagnosis and high grade transformation is described (38).  Management is usually by wide 
local excision (39-40) and there is an overall excellent prognosis with a 10 year disease 
specific survival of 96.4% (40).  The incidence of lymph node metastases ranges from to 0% 
to 17% (41-44), and this behaviour often seemed at odds with the low grade designation.  
More aggressive behaviour is associated with a base of tongue location and a papillary or 
cribriform architecture (43-44).  These features are seen in tumours described under the 
term cribriform adenocarcinoma of tongue and subsequently cribriform adenocarcinoma of 
minor salivary gland (CAMSG) (45-46).  CAMSG has a metastatic rate of 70-100% (45-46) 
exceeding that of PAC.  The microscopic features of CAMSG can overlap with those of PAC 
(44) and CAMSG is regarded by the WHO as an emerging entity and is not separated from 
PAC.  CAMSG is however recognised as a distinct entity by many pathologists who will likely 
continue to report it as a distinct tumour and clinicians need to be aware of its more 
aggressive course. 
 
The WHO emphasises that appropriate management of carcinoma ex-pleomorphic adenoma 
is determined by the extent of invasion and the type of carcinoma.  The authors of the Royal 
College of Pathologists dataset for salivary carcinomas further emphasise that “the 
prognosis of the carcinomatous component is poorer than that of comparable carcinomas 
developing de novo” (47).   It is generally accepted that an intracapsular carcinoma ex-
pleomorphic adenoma follows an essentially benign course after conservative surgical 
management (48-49).  Minimal invasion is also associated with a relatively favourable 
prognosis (49).  However, the cut off for what constitutes minimally invasive is not clear.  The 
WHO (1) cites a range of 4-6mm and the Royal College of Pathologists (47) a range of 5–6 
mm, both acknowledging the need for further validation.  The issue as to the correct cut off is 
compounded by difficulties in its measurement that can be caused by multifocality, 
multinodular growth or an incomplete capsule.  Furthermore, the importance of extent of 
invasion can be superseded by grade of carcinoma.  For example, Griffith et al. (50) 
described 3 cases of salivary duct carcinoma ex-pleomorphic adenoma (a high grade 
carcinoma) with less than 2mm extracapsular invasion.  Despite this “minimal invasion”, 2 
cases gave rise to metastatic disease and one patient had died from their disease after 16 
months.  Determination of the prognosis and correct management for carcinoma ex-
pleomorphic adenoma requires careful clinico-pathological correlation.  Factors including 
extent of invasion, carcinoma grade and stage need to be assessed together.  It would seem 
incorrect to base treatment solely on the extent of invasion. 
 
Key points 
• Sclerosing polycystic adenosis is listed as a non -neoplastic epithelial lesion but there 
is some evidence that it may be a neoplasm and carries a significant recurrence rate. 
• Secretory carcinoma has a higher metastatic rate than acinic cell carcinoma and has 
potential for targeted therapy, making correct identification of this new entity essential.   
• Intraductal carcinoma with the usual low grade appearances can be managed 
effectively by parotidectomy. 
• Polymorphous adenocarcinoma is the new designation for polymorphous low grade 
adenocarcinoma, recognising a wider spectrum of behaviour.  
    
Tumours of the oral cavity and mobile tongue. 
Tumours of the oral cavity and mobile tongue have been separated from those of the 
oropharynx reflecting the importance of HPV in carcinoma of the tonsils and oropharynx 
(51).  HPV associated oral epithelial dysplasia is described as lesions occurring mostly in 
adult men on the ventral or lateral tongue lesion (52).  Microscopy shows full-thickness 
dysplasia with frequent apoptosis.  However, the risk of malignant transformation is 
unknown. 
 
The WHO group was unable to produce a unified dysplasia grading that could be applied to 
all aerodigestive tract sites.  Separate dysplasia grading systems are kept for larynx and oral 
cavity, reflecting the differences in aetiology and the very different normal structure of the 
epithelium at these sites.  Some have felt that one unified system would promote 
reproducible grading but this has so far proved impossible to define.  Perhaps it will be an 
objective for the next edition. 
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Figure Legends  
Figure 1.  Slerosing polycystic adenosis arising in the parotid gland  
The photomicrographs show slerosing polycystic adenosis arising in the parotid gland.  
There is a typically circumscribed lobular proliferation of ducts and acini within a sclerotic 
stroma (A) (H&E x2.5).  Distinctive brightly eosinophilic granules are seen in some cells (B) 
(H&E x10).  
Figure 2.   Secretory carcinoma in the parotid gland 
The photomicrographs show a secretory carcinoma in the parotid gland.   The neoplasm has 
microcystic surface and abundant secretory material (2A) (H&E x5).   There is a monophasic 
cell population showing abundant bubbly cytoplasm (2B) (H&E x10). 
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WHO is in and WHO is out of the mouth, salivary glands, and jaws 
sections of the 4th edition of the WHO classification of head and neck 
tumours 
 
 
Abstract 
This review of changes to the 4th edition of the WHO classification of head and neck tumours 
focuses on their impact on the surgical care of diseases that affect the salivary glands, jaws, 
and oral cavity.  Updates to the chapter on the salivary glands include the addition of 
secretory carcinoma and sclerosing polycystic adenosis.  The odontogenic cysts are back, and 
the odontogenic keratocyst is listed among them, as it has now lost its brief and confusing 
designation as a neoplasm.   The newly-defined sclerosing odontogenic carcinoma and 
primordial odontogenic tumour have been added.  Oropharyngeal tumours have been 
separated from those of the oral cavity, which reflects the importance of HPV in carcinoma of 
the tonsils.  The problems of grading oral epithelial dysplasia persist.   
 
Keywords: Pathology, Tumour, Oral, Salivary, Jaws, WHO, Classification 
 
Introduction 
 
The WHO text
1
 is a classification of tumours with an emphasis on neoplasms, and it aims to 
achieve consistent nomenclature and diagnosis of tumours across the globe.  This should 
facilitate epidemiological research with accurate comparisons of incidence among countries 
as well as effective transfer of treatments and diagnostic tests. In its 4th edition, the WHO 
classification of head and neck tumours contains new additions, updates, and 
*Manuscript with title (excluding any author details including names and affiliations)
Click here to view linked References
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reclassifications.
1
 The changes reflect an improved understanding of the morphological and 
behavioural range of head and neck tumours.  There is much greater detail on the molecular 
drivers of neoplasia, and it is hoped that this will facilitate greater use of targeted treatments 
in the future.  
 
Odontogenic and maxillofacial bone tumours 
 
This chapter has been expanded to include odontogenic cysts (omitted from the previous 
edition
2
) as well as benign and malignant tumours of bone and cartilage.   There have been 
changes in the nomenclature of odontogenic tumours, some of which provide a helpful 
simplification, but others that have the potential to cause confusion.    
 
Malignant odontogenic tumours 
 
The classification of malignant odontogenic tumours has been simplified.  There is now only 
one ameloblastic carcinoma, one primary intraosseous carcinoma, and one odontogenic 
sarcoma.  Odontogenic carcinosarcoma (eliminated from the previous edition) has been 
included, with reference to a small number of well-defined cases.  Metastasising 
ameloblastoma has been moved from the malignant to the benign section, which brings it into 
line with the benign metastasising pleomorphic adenoma, as it does show a benign 
microscopic appearance at both the primary and metastatic sites.  The most common sites of 
metastases are the lungs, followed by the cervical lymph nodes.  The overall mean 5-year 
survival is just 44%.  Patients with cervical lymph node metastases alone who are managed 
by resection seem to survive better, although data are limited.
3
   
 
 3 
The only newly-defined malignant odontogenic tumour included is the rare, and 
recently described, sclerosing odontogenic carcinoma.
4-9
   Reported cases have been in men 
and women between 40-70 years of age.  It presents as an expansile mass, sometimes with 
nerve signs.  There is a relatively even distribution between the maxilla and mandible, with 
variable cortical destruction and tooth resorption. 
4-8
 The cytological features are bland but 
there is an aggressive pattern of infiltration into muscles and nerves.  The carcinoma extends 
beyond what seem at operation to be clear margins,
3
  and the tumour recurs after curettage 
alone.
5
  Resection with a 5 mm margin has been recommended.
8
   Neck dissection, 
chemotherapy, and radiotherapy have also been used.
4,5
  However, no metastases or disease- 
related deaths have been reported, and the need for adjunctive treatment is not clear. It is 
important to recognise this entity, so that its aggressive histological appearance does not lead 
to overtreatment.    
 
Benign odontogenic tumours 
 
Ameloblastic fibrodentinoma and ameloblastic fibro-odontoma are now considered by most 
authorities to be developing odontomas, and have been removed.  The odontoameloblastoma 
was previously described as a distinct entity that combined the features of an ameloblastoma 
with those of an odontoma.  It still has a brief mention in the section on ameloblastomas, as it 
is now considered to be an ameloblastoma that has grown around, or originated in, the follicle 
of an odontoma or developing tooth.  The ossifying fibroma is given a section among the 
benign odontogenic tumours under the term cemento-ossifying fibroma, which better reflects 
its odontogenic origin but has no implications for its management.  
 
 4 
The classification of ameloblastomas remains contentious, particularly regarding 
unicystic types.  The term ameloblastoma, solid/multicystic type, has been replaced by 
ameloblastoma without further qualification, which may cause some confusion.  Many 
pathologists are likely to continue using the term solid/multicystic to differentiate the 
conventional ameloblastoma from unicystic and other variants.  The ameloblastoma, 
unicystic type, retains its full and descriptive name.  The unicystic ameloblastoma without 
invasion of its wall can probably be managed more conservatively than the solid/multicystic 
type, 
10, 11  
but there is a lack of follow-up studies and unicystic ameloblastomas do seem to 
recur, albeit less often than solid/multicystic types.  Clear differentiation between types of 
ameloblastoma therefore seems essential, although diagnosis of a unicystic ameloblastoma 
without mural invasion can be confirmed only on examination of the entire excised specimen.  
 
 It remains to be seen to what extent this new classification will be accepted, and it 
seems likely that the growing understanding of the mutational drivers of ameloblastomas will 
assist in the prediction of their behaviour and allow for more targeted treatments.
12
 A 
considerable proportion of ameloblastomas carry a mutation of BRAF, 
13
 as do some 
melanomas and thyroid carcinomas,  and there is emerging evidence that ameloblastomas that 
carry this BRAF mutation follow a more aggressive course.
14
 
 
The only newly-defined benign odontogenic tumour that has been added is the 
primordial odontogenic tumour, which has been described in a series of six patients, 
15
 all in 
the first two decades of life, with an even distribution between the sexes.   All presented with 
an asymptomatic swelling in the posterior mandible (n=5) or the posterior maxilla (n=1).   
Images showed well-defined radiolucencies (35-90 mm in maximum dimension) associated 
with unerupted, variably-resorbed or displaced teeth in apparent pericoronal relations.  The 
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tumours were solid and well-circumscribed, and comprised loose fibrous tissue with tissue 
similar to the dental papilla and a characteristic complete peripheral lining of cuboidal to 
columnar epithelium.  The lesions were easily enucleated and no recurrences reported with up 
to 20 years’ follow up. 
 
Odontogenic cysts 
 
Odontogenic cysts were a notable omission from the previous edition, which caused 
difficulties both because there is overlap between the histological appearances of cysts and 
odontogenic and salivary neoplasms, and because of changes in terminology made at the 
same time.  In the previous edition, odontogenic keratocysts (OKC) and calcifying 
odontogenic cysts (COC) were listed as keratocystic odontogenic tumours and calcifying 
cystic odontogenic tumours, respectively.  This led to confusion, and the nomenclature was 
not widely accepted.  The propensity for recurrence, together with association with mutations 
of the Drosophila segment polarity gene Patched (PTCH) gene,
16 
had been taken as 
supportive of a neoplastic designation for the OKC.  However, not all OKC possess 
identifiable PTCH mutations 
17
 and it was not clear whether the neoplastic designation was 
meant to apply to all OKC or just a subset, as cysts were omitted.  The 2017 WHO panel did 
not think there was sufficient evidence to justify its classification as a neoplasm, and the 
designations OKC and COC are back as the preferred terms, though the 2005 terms remain 
acceptable synonyms.  
 
Maxillofacial bone tumours 
 
 6 
 Benign and malignant tumours of bone and cartilage are now described in the same chapter 
as the odontogenic tumours, which allows for features specific to the gnathic bones to be 
emphasised.  In terms of care of patients this is most relevant for osteosarcoma, which has 
less propensity to metastasise when it arises in the gnathic bones than in other skeletal sites.  
Indeed, resection with clear margins is the most important prognostic factor for osteosarcoma 
of the jaws, and the role of (neo)adjuvant treatment remains controversial.
18
   
 
Key points 
• Sclerosing odontogenic carcinoma is a recently-described entity that, despite its 
aggressive microscopic appearance, carries a good prognosis.  No metastatic spread or 
disease-related deaths have so far been reported. 
• Metastasising ameloblastoma is now defined as benign, despite its appreciable 
mortality. 
• Ameloblastic fibrodentinoma and ameloblastic fibro-odontoma are considered to be 
stages in the development of odontomas and may be treated by enucleation. 
• Primordial odontogenic tumour is an emerging entity that is seen in young people and 
seems to be adequately managed by enucleation. 
• “Odontogenic keratocyst” has been reinstated as the preferred term for a keratocystic 
odontogenic tumour, which reflects its probable non-neoplastic nature. 
 
Tumours of the salivary glands 
 
Many different epithelial tumours arise in the salivary glands, and many subtypes have been 
suggested.   Only well-documented epithelial neoplasms are included, often with supporting 
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genetic data.  The soft tissue section of the chapter has been expanded and a section on non-
neoplastic epithelial lesions added.      
 
Benign salivary tumours 
 
No recently recognised tumours have been added to this section.  Metastasising pleomorphic 
adenoma was previously listed as a distinct entity in the section on malignant tumours, and it 
now occupies a subcategory of pleomorphic adenoma within the section on benign tumours.  
Metastasising pleomorphic adenoma cannot be distinguished histologically from a typical 
pleomorphic adenoma and is diagnosed only on detection of metastases, usually after many 
local recurrences.  In a well-documented series of 11 patients, two died as a direct result of 
metastatic tumours. 
19
 However, recognition of the lesion as a benign entity may allow 
excision of more aggressive metastases, particularly when there are few of them.  
 
Non-neoplastic epithelial lesions  
  
The new additions of nodular oncocytic hyperplasia, intercalated ductal hyperplasia, and 
sclerosing polycystic adenosis are included in this section.  Nodular oncocytic hyperplasia is 
a benign non-neoplastic nodular proliferation that occurs in the parotid gland.  Intercalated 
duct hyperplasia is similarly rare, and usually an incidental finding in excisions of other 
salivary tumours. 
 
Sclerosing polycystic adenosis (Fig. 1) was described in the 1990s 
20
 and named for 
its resemblance to fibrocystic change and sclerosing adenosis of the breast.  It presents as a 
painless, slow-growing mass usually in the parotid gland, less often in the submandibular 
 8 
gland, and even more rarely in the minor glands.
20, 21
  Both men and women are affected, 
over a wide age range.
20, 21
 The lesion comprises a lobular, well-circumscribed proliferation 
of ducts and acini.  Cytological atypia can be present 
20, 23
 and there is evidence that this may 
be a neoplastic rather than reactive process. 
23
 A single case of malignant transformation has 
been described after multiple recurrences.
24
 Treatment is by complete excision with good 
margins, but a recurrence rate of 19% has been reported.
25
  
 
Malignant tumours 
 
The only recently defined tumour that has been added to this chapter is secretory carcinoma 
(Fig. 2).  This was previously described in most publications as “mammary analogue 
secretory carcinoma (MASC)” because of its morphological similarity to secretory carcinoma 
of breast, which is caused by the same ETV6-NTRK3 translocation.  The tumour arises in the 
major and minor glands over a wide age range and without particular sex bias. 
26, 27
 It usually 
presents as a painless mass 
26, 28 
with a well-circumscribed but unencapsulated periphery.  
The carcinoma looks cytologically low grade 
26, 27
but has a 20% incidence of metastases.
28
  
Prognosis is generally good but worsens with increasing stage, high grade transformation, 
and possibly atypical fusion transcripts.
26, 29, 30
   Before its definition, cases would probably 
have been diagnosed as acinic cell carcinoma. 
31
 The higher metastatic rate and possibility of 
targeted treatments, which take advantage of the known translocation, 
32 
make correct 
diagnosis essential.  
 
Intraductal carcinoma is included as a section that encompasses entities previously 
described as low grade cribriform cystadenocarcinoma or low grade salivary duct carcinoma.  
These rare carcinomas have what is described as an intraductal growth pattern, and are 
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considered to be non-invasive/in situ.   They usually present as a symptomless swelling, 
usually in the parotid gland, and rarely in the submandibular or minor glands. 
33-36
 Ages of 
patients in the largest series ranged from 32 to 94 years without particular sex bias.
33-35
 The 
designation “intraductal” is based on the well-circumscribed architecture and the presence of 
an intact periphery of myoepithelial cells that surround an intraluminal proliferation of ductal 
cells.  The cytological features are usually low grade.  The view that an intact layer of 
surrounding myoepithelial cells indicates that the proliferation is an intraductal one seems to 
assume that the myoepithelial cells are not themselves neoplastic, but the justification for this 
assumption is not clear.  Management is by parotidectomy and no recurrences or metastatic 
disease have been reported in cases with the usual low grade features.
34,35
   High grade 
cytology has been associated with multiple recurrences, and high-grade transformation to 
widely invasive high-grade adenosquamous carcinoma with metastatic disease has also been 
described.
33, 37 
 
Polymorphous low grade adenocarcinoma has been renamed polymorphous 
adenocarcinoma (PAC).  The low grade descriptive term has now been dropped as, while 
most are low grade, more aggressive forms are included within the range of this diagnosis 
and high grade transformation has been described.
38
 Management is usually by wide local 
excision
39, 40
 and an overall excellent prognosis with a 10-year disease-specific survival of 
96.4% has been reported.
40
 The incidence of lymph node metastases ranges from 0 to 17% ,
41-
44
 and this behaviour often seemed at odds with the low grade designation.  More aggressive 
behaviour is associated with it when is situated at the base of  the tongue and has papillary or 
cribriform architecture.
43,44
  These features are seen in tumours described under the term 
“cribriform adenocarcinoma of tongue” and subsequently “cribriform adenocarcinoma of 
minor salivary gland” (CAMSG).45, 46  CAMSG has a metastatic rate of 70%-100%, which 
exceeds that of PAC.
45, 46
  The microscopic features of CAMSG can overlap with those of 
PAC, 
44 
and CAMSG is regarded by the WHO as an emerging entity and is not separated 
from PAC.  CAMSG is, however, recognised as a distinct entity by many pathologists who 
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will probably continue to report it as a distinct tumour, and clinicians need to be aware of its 
more aggressive course. 
 
The WHO emphasises that appropriate management of carcinoma ex-pleomorphic 
adenoma is governed by the extent of invasion and the type of carcinoma.  The authors of the 
Royal College of Pathologists dataset for salivary carcinomas further emphasise that “the 
prognosis of the carcinomatous component is poorer than that of comparable carcinomas 
developing de novo”.47   It is generally accepted that an intracapsular carcinoma ex-
pleomorphic adenoma follows an essentially benign course after conservative surgical 
management.
48,49
  Minimal invasion is also associated with a relatively favourable 
prognosis.
49
  However, the cut-off point for what constitutes minimally invasive is not clear.  
The WHO
1
 cites a range of 4-6 mm and the Royal College of Pathologists 
47
 a range of 5–6 
mm, but both acknowledge the need for further validation.  The issue of the correct cut-off 
point is compounded by difficulties in its measurement that can be caused by its multifocal 
and multinodular growth, or an incomplete capsule. The importance of extent of invasion can 
also be superseded by the grade of carcinoma.  For example, Griffith et al 
50
 described three 
cases of salivary duct carcinoma ex-pleomorphic adenoma (a high grade carcinoma) with less 
than 2 mm extracapsular invasion.  Despite this “minimal invasion”, two of them developed 
metastatic disease, and one died of the disease after 16 months.  Establishment of the 
prognosis, and correct management of carcinoma ex-pleomorphic adenoma, require careful 
clinicopathological correlation.  Factors to consider include extent of invasion, grade of 
carcinoma, and stage, and these must be assessed together.  It seems wrong to base treatment 
solely on the extent of invasion. 
 
Key points 
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• Sclerosing polycystic adenosis is listed as a non -neoplastic epithelial lesion, but there 
is some evidence that it may be a neoplasm and it carries an appreciable rate of recurrence. 
• Secretory carcinoma has a higher metastatic rate than acinic cell carcinoma, and has 
potential for targeted treatment, which makes correct identification of this new entity 
essential.   
• Intraductal carcinoma with the usual low grade appearances can be managed 
effectively by parotidectomy. 
• Polymorphous adenocarcinoma is the new designation for polymorphous low grade 
adenocarcinoma, and this includes a wider range of behaviour.  
    
Tumours of the oral cavity and mobile tongue 
 
Tumours of the oral cavity and mobile tongue have been separated from those of the 
oropharynx, which reflects the importance of HPV in carcinoma of the tonsils and 
oropharynx.
51
 HPV-associated oral epithelial dysplasia is described as a lesion that presents 
mostly in adult men, and on the ventral or lateral tongue. 
52
 Microscopy shows full-thickness 
dysplasia with frequent apoptosis.  However, the risk of malignant transformation is 
unknown. 
 
The WHO group was unable to produce a unified grading of dysplasia that could be 
applied to all sites in the aerodigestive tract.  Separate systems for grading dysplasia are kept 
for the larynx and oral cavity, which reflects the differences in aetiology and the different 
structure of the normal epithelium at these sites.  Some have thought that one unified system 
would promote reproducible grading, but this has so far proved impossible to define.  Perhaps 
it will be an objective for the next edition. 
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Legends to Figures  
Figure 1.  Photomicrographs showing sclerosing polycystic adenosis arising in the parotid 
gland. (A)There is a typically circumscribed lobular proliferation of ducts and acini within a 
sclerotic stroma ( haematoxylin and eosin, original magnification x 2.5). (B) Distinctive 
brightly eosinophilic granules are seen in some cells (haematoxylin and eosin, original 
magnification x 10).  
Figure 2.   Photomicrographs showing secretory carcinoma in the parotid gland. 
(A)The neoplasm has a microcystic surface and abundant secretory material (haematoxylin 
and eosin, original magnification x 5).  (B) There is a monophasic cell population showing 
abundant bubbly cytoplasm (haematoxylin and eosin, original magnification x 10). 
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